

Global Neurodegenerative Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

<https://marketpublishers.com/r/G7681DB79DE8EN.html>

Date: July 2024

Pages: 133

Price: US\$ 3,480.00 (Single User License)

ID: G7681DB79DE8EN

Abstracts

According to our (Global Info Research) latest study, the global Neurodegenerative Drugs market size was valued at USD 118360 million in 2023 and is forecast to a readjusted size of USD 174250 million by 2030 with a CAGR of 5.7% during review period.

Neurodegenerative drugs are medications used to manage and alleviate symptoms associated with neurodegenerative diseases. They may target various aspects of disease progression, such as cognitive function, motor symptoms, and inflammation.

The market for neurodegenerative drugs is driven by the growing burden of neurodegenerative diseases and the need for effective and disease-modifying treatments. The market's growth is also influenced by ongoing research in neuroscience and the development of novel drug candidates targeting specific neurodegenerative pathways.

The Global Info Research report includes an overview of the development of the Neurodegenerative Drugs industry chain, the market status of Parkinson's Disease (NMDA, SSRIs), Huntington Disease (NMDA, SSRIs), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Neurodegenerative Drugs.

Regionally, the report analyzes the Neurodegenerative Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Neurodegenerative Drugs market, with robust domestic demand, supportive

policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Neurodegenerative Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Neurodegenerative Drugs industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (MT), revenue generated, and market share of different by Type (e.g., NMDA, SSRIs).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Neurodegenerative Drugs market.

Regional Analysis: The report involves examining the Neurodegenerative Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Neurodegenerative Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Neurodegenerative Drugs:

Company Analysis: Report covers individual Neurodegenerative Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Neurodegenerative Drugs This may involve surveys, interviews, and

analysis of consumer reviews and feedback from different by Application (Parkinson's Disease, Huntington Disease).

Technology Analysis: Report covers specific technologies relevant to Neurodegenerative Drugs. It assesses the current state, advancements, and potential future developments in Neurodegenerative Drugs areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Neurodegenerative Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Neurodegenerative Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type

NMDA

SSRIs

Dopamine Inhibitors

Market segment by Application

Parkinson's Disease

Huntington Disease

Amyotrophic Lateral Sclerosis

Alzheimer's Disease

Major players covered

Novartis

Pfizer

Merck Serono

Biogen Idec

TEVA

UCB

Boehringer Ingelheim

Sanofi

GlaxoSmithKline

Livzon Pharmaceutical

Haisco Pharmaceutical

Jingxin Pharmaceutical

Dongcheng Biochemicals

Hisun Pharmaceutical

Luye Pharma

Ark Pharmaceutical

Kanghong Pharmaceutical

Huahai Pharmaceutical

BORA PHARMACEUTICALS

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Neurodegenerative Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Neurodegenerative Drugs, with price, sales, revenue and global market share of Neurodegenerative Drugs from 2019 to 2024.

Chapter 3, the Neurodegenerative Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Neurodegenerative Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales

quantity, consumption value and market share for key countries in the world, from 2017 to 2023. and Neurodegenerative Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Neurodegenerative Drugs.

Chapter 14 and 15, to describe Neurodegenerative Drugs sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope of Neurodegenerative Drugs

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Type

1.3.1 Overview: Global Neurodegenerative Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030

1.3.2 NMDA

1.3.3 SSRIs

1.3.4 Dopamine Inhibitors

1.4 Market Analysis by Application

1.4.1 Overview: Global Neurodegenerative Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030

1.4.2 Parkinson's Disease

1.4.3 Huntington Disease

1.4.4 Amyotrophic Lateral Sclerosis

1.4.5 Alzheimer's Disease

1.5 Global Neurodegenerative Drugs Market Size & Forecast

1.5.1 Global Neurodegenerative Drugs Consumption Value (2019 & 2023 & 2030)

1.5.2 Global Neurodegenerative Drugs Sales Quantity (2019-2030)

1.5.3 Global Neurodegenerative Drugs Average Price (2019-2030)

2 MANUFACTURERS PROFILES

2.1 Novartis

2.1.1 Novartis Details

2.1.2 Novartis Major Business

2.1.3 Novartis Neurodegenerative Drugs Product and Services

2.1.4 Novartis Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.1.5 Novartis Recent Developments/Updates

2.2 Pfizer

2.2.1 Pfizer Details

2.2.2 Pfizer Major Business

2.2.3 Pfizer Neurodegenerative Drugs Product and Services

2.2.4 Pfizer Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

- 2.2.5 Pfizer Recent Developments/Updates
- 2.3 Merck Serono
 - 2.3.1 Merck Serono Details
 - 2.3.2 Merck Serono Major Business
 - 2.3.3 Merck Serono Neurodegenerative Drugs Product and Services
 - 2.3.4 Merck Serono Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.3.5 Merck Serono Recent Developments/Updates
- 2.4 Biogen Idec
 - 2.4.1 Biogen Idec Details
 - 2.4.2 Biogen Idec Major Business
 - 2.4.3 Biogen Idec Neurodegenerative Drugs Product and Services
 - 2.4.4 Biogen Idec Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.4.5 Biogen Idec Recent Developments/Updates
- 2.5 TEVA
 - 2.5.1 TEVA Details
 - 2.5.2 TEVA Major Business
 - 2.5.3 TEVA Neurodegenerative Drugs Product and Services
 - 2.5.4 TEVA Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.5.5 TEVA Recent Developments/Updates
- 2.6 UCB
 - 2.6.1 UCB Details
 - 2.6.2 UCB Major Business
 - 2.6.3 UCB Neurodegenerative Drugs Product and Services
 - 2.6.4 UCB Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.6.5 UCB Recent Developments/Updates
- 2.7 Boehringer Ingelheim
 - 2.7.1 Boehringer Ingelheim Details
 - 2.7.2 Boehringer Ingelheim Major Business
 - 2.7.3 Boehringer Ingelheim Neurodegenerative Drugs Product and Services
 - 2.7.4 Boehringer Ingelheim Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.7.5 Boehringer Ingelheim Recent Developments/Updates
- 2.8 Sanofi
 - 2.8.1 Sanofi Details
 - 2.8.2 Sanofi Major Business

- 2.8.3 Sanofi Neurodegenerative Drugs Product and Services
- 2.8.4 Sanofi Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.8.5 Sanofi Recent Developments/Updates
- 2.9 GlaxoSmithKline
 - 2.9.1 GlaxoSmithKline Details
 - 2.9.2 GlaxoSmithKline Major Business
 - 2.9.3 GlaxoSmithKline Neurodegenerative Drugs Product and Services
 - 2.9.4 GlaxoSmithKline Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.9.5 GlaxoSmithKline Recent Developments/Updates
- 2.10 Livzon Pharmaceutical
 - 2.10.1 Livzon Pharmaceutical Details
 - 2.10.2 Livzon Pharmaceutical Major Business
 - 2.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Product and Services
 - 2.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.10.5 Livzon Pharmaceutical Recent Developments/Updates
- 2.11 Haisco Pharmaceutical
 - 2.11.1 Haisco Pharmaceutical Details
 - 2.11.2 Haisco Pharmaceutical Major Business
 - 2.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Product and Services
 - 2.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.11.5 Haisco Pharmaceutical Recent Developments/Updates
- 2.12 Jingxin Pharmaceutical
 - 2.12.1 Jingxin Pharmaceutical Details
 - 2.12.2 Jingxin Pharmaceutical Major Business
 - 2.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Product and Services
 - 2.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.12.5 Jingxin Pharmaceutical Recent Developments/Updates
- 2.13 Dongcheng Biochemicals
 - 2.13.1 Dongcheng Biochemicals Details
 - 2.13.2 Dongcheng Biochemicals Major Business
 - 2.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Product and Services
 - 2.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.13.5 Dongcheng Biochemicals Recent Developments/Updates

2.14 Hisun Pharmaceutical

2.14.1 Hisun Pharmaceutical Details

2.14.2 Hisun Pharmaceutical Major Business

2.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Product and Services

2.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.14.5 Hisun Pharmaceutical Recent Developments/Updates

2.15 Luye Pharma

2.15.1 Luye Pharma Details

2.15.2 Luye Pharma Major Business

2.15.3 Luye Pharma Neurodegenerative Drugs Product and Services

2.15.4 Luye Pharma Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.15.5 Luye Pharma Recent Developments/Updates

2.16 Ark Pharmaceutical

2.16.1 Ark Pharmaceutical Details

2.16.2 Ark Pharmaceutical Major Business

2.16.3 Ark Pharmaceutical Neurodegenerative Drugs Product and Services

2.16.4 Ark Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.16.5 Ark Pharmaceutical Recent Developments/Updates

2.17 Kanghong Pharmaceutical

2.17.1 Kanghong Pharmaceutical Details

2.17.2 Kanghong Pharmaceutical Major Business

2.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Product and Services

2.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.17.5 Kanghong Pharmaceutical Recent Developments/Updates

2.18 Huahai Pharmaceutical

2.18.1 Huahai Pharmaceutical Details

2.18.2 Huahai Pharmaceutical Major Business

2.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Product and Services

2.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.18.5 Huahai Pharmaceutical Recent Developments/Updates

2.19 BORA PHARMACEUTICALS

2.19.1 BORA PHARMACEUTICALS Details

2.19.2 BORA PHARMACEUTICALS Major Business

2.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Product and Services

2.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.19.5 BORA PHARMACEUTICALS Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: NEURODEGENERATIVE DRUGS BY MANUFACTURER

3.1 Global Neurodegenerative Drugs Sales Quantity by Manufacturer (2019-2024)

3.2 Global Neurodegenerative Drugs Revenue by Manufacturer (2019-2024)

3.3 Global Neurodegenerative Drugs Average Price by Manufacturer (2019-2024)

3.4 Market Share Analysis (2023)

3.4.1 Producer Shipments of Neurodegenerative Drugs by Manufacturer Revenue (\$MM) and Market Share (%): 2023

3.4.2 Top 3 Neurodegenerative Drugs Manufacturer Market Share in 2023

3.4.2 Top 6 Neurodegenerative Drugs Manufacturer Market Share in 2023

3.5 Neurodegenerative Drugs Market: Overall Company Footprint Analysis

3.5.1 Neurodegenerative Drugs Market: Region Footprint

3.5.2 Neurodegenerative Drugs Market: Company Product Type Footprint

3.5.3 Neurodegenerative Drugs Market: Company Product Application Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Neurodegenerative Drugs Market Size by Region

4.1.1 Global Neurodegenerative Drugs Sales Quantity by Region (2019-2030)

4.1.2 Global Neurodegenerative Drugs Consumption Value by Region (2019-2030)

4.1.3 Global Neurodegenerative Drugs Average Price by Region (2019-2030)

4.2 North America Neurodegenerative Drugs Consumption Value (2019-2030)

4.3 Europe Neurodegenerative Drugs Consumption Value (2019-2030)

4.4 Asia-Pacific Neurodegenerative Drugs Consumption Value (2019-2030)

4.5 South America Neurodegenerative Drugs Consumption Value (2019-2030)

4.6 Middle East and Africa Neurodegenerative Drugs Consumption Value (2019-2030)

5 MARKET SEGMENT BY TYPE

5.1 Global Neurodegenerative Drugs Sales Quantity by Type (2019-2030)

5.2 Global Neurodegenerative Drugs Consumption Value by Type (2019-2030)

5.3 Global Neurodegenerative Drugs Average Price by Type (2019-2030)

6 MARKET SEGMENT BY APPLICATION

- 6.1 Global Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
- 6.2 Global Neurodegenerative Drugs Consumption Value by Application (2019-2030)
- 6.3 Global Neurodegenerative Drugs Average Price by Application (2019-2030)

7 NORTH AMERICA

- 7.1 North America Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
- 7.2 North America Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
- 7.3 North America Neurodegenerative Drugs Market Size by Country
 - 7.3.1 North America Neurodegenerative Drugs Sales Quantity by Country (2019-2030)
 - 7.3.2 North America Neurodegenerative Drugs Consumption Value by Country (2019-2030)
 - 7.3.3 United States Market Size and Forecast (2019-2030)
 - 7.3.4 Canada Market Size and Forecast (2019-2030)
 - 7.3.5 Mexico Market Size and Forecast (2019-2030)

8 EUROPE

- 8.1 Europe Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
- 8.2 Europe Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
- 8.3 Europe Neurodegenerative Drugs Market Size by Country
 - 8.3.1 Europe Neurodegenerative Drugs Sales Quantity by Country (2019-2030)
 - 8.3.2 Europe Neurodegenerative Drugs Consumption Value by Country (2019-2030)
 - 8.3.3 Germany Market Size and Forecast (2019-2030)
 - 8.3.4 France Market Size and Forecast (2019-2030)
 - 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
 - 8.3.6 Russia Market Size and Forecast (2019-2030)
 - 8.3.7 Italy Market Size and Forecast (2019-2030)

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
- 9.2 Asia-Pacific Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
- 9.3 Asia-Pacific Neurodegenerative Drugs Market Size by Region
 - 9.3.1 Asia-Pacific Neurodegenerative Drugs Sales Quantity by Region (2019-2030)
 - 9.3.2 Asia-Pacific Neurodegenerative Drugs Consumption Value by Region

(2019-2030)

9.3.3 China Market Size and Forecast (2019-2030)

9.3.4 Japan Market Size and Forecast (2019-2030)

9.3.5 Korea Market Size and Forecast (2019-2030)

9.3.6 India Market Size and Forecast (2019-2030)

9.3.7 Southeast Asia Market Size and Forecast (2019-2030)

9.3.8 Australia Market Size and Forecast (2019-2030)

10 SOUTH AMERICA

10.1 South America Neurodegenerative Drugs Sales Quantity by Type (2019-2030)

10.2 South America Neurodegenerative Drugs Sales Quantity by Application
(2019-2030)

10.3 South America Neurodegenerative Drugs Market Size by Country

10.3.1 South America Neurodegenerative Drugs Sales Quantity by Country
(2019-2030)

10.3.2 South America Neurodegenerative Drugs Consumption Value by Country
(2019-2030)

10.3.3 Brazil Market Size and Forecast (2019-2030)

10.3.4 Argentina Market Size and Forecast (2019-2030)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Neurodegenerative Drugs Sales Quantity by Type
(2019-2030)

11.2 Middle East & Africa Neurodegenerative Drugs Sales Quantity by Application
(2019-2030)

11.3 Middle East & Africa Neurodegenerative Drugs Market Size by Country

11.3.1 Middle East & Africa Neurodegenerative Drugs Sales Quantity by Country
(2019-2030)

11.3.2 Middle East & Africa Neurodegenerative Drugs Consumption Value by Country
(2019-2030)

11.3.3 Turkey Market Size and Forecast (2019-2030)

11.3.4 Egypt Market Size and Forecast (2019-2030)

11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)

11.3.6 South Africa Market Size and Forecast (2019-2030)

12 MARKET DYNAMICS

- 12.1 Neurodegenerative Drugs Market Drivers
- 12.2 Neurodegenerative Drugs Market Restraints
- 12.3 Neurodegenerative Drugs Trends Analysis
- 12.4 Porters Five Forces Analysis
 - 12.4.1 Threat of New Entrants
 - 12.4.2 Bargaining Power of Suppliers
 - 12.4.3 Bargaining Power of Buyers
 - 12.4.4 Threat of Substitutes
 - 12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

- 13.1 Raw Material of Neurodegenerative Drugs and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Neurodegenerative Drugs
- 13.3 Neurodegenerative Drugs Production Process
- 13.4 Neurodegenerative Drugs Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

- 14.1 Sales Channel
 - 14.1.1 Direct to End-User
 - 14.1.2 Distributors
- 14.2 Neurodegenerative Drugs Typical Distributors
- 14.3 Neurodegenerative Drugs Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

- 16.1 Methodology
- 16.2 Research Process and Data Source
- 16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Neurodegenerative Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Table 2. Global Neurodegenerative Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030

Table 3. Novartis Basic Information, Manufacturing Base and Competitors

Table 4. Novartis Major Business

Table 5. Novartis Neurodegenerative Drugs Product and Services

Table 6. Novartis Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 7. Novartis Recent Developments/Updates

Table 8. Pfizer Basic Information, Manufacturing Base and Competitors

Table 9. Pfizer Major Business

Table 10. Pfizer Neurodegenerative Drugs Product and Services

Table 11. Pfizer Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 12. Pfizer Recent Developments/Updates

Table 13. Merck Serono Basic Information, Manufacturing Base and Competitors

Table 14. Merck Serono Major Business

Table 15. Merck Serono Neurodegenerative Drugs Product and Services

Table 16. Merck Serono Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 17. Merck Serono Recent Developments/Updates

Table 18. Biogen Idec Basic Information, Manufacturing Base and Competitors

Table 19. Biogen Idec Major Business

Table 20. Biogen Idec Neurodegenerative Drugs Product and Services

Table 21. Biogen Idec Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 22. Biogen Idec Recent Developments/Updates

Table 23. TEVA Basic Information, Manufacturing Base and Competitors

Table 24. TEVA Major Business

Table 25. TEVA Neurodegenerative Drugs Product and Services

Table 26. TEVA Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 27. TEVA Recent Developments/Updates

Table 28. UCB Basic Information, Manufacturing Base and Competitors

- Table 29. UCB Major Business
- Table 30. UCB Neurodegenerative Drugs Product and Services
- Table 31. UCB Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 32. UCB Recent Developments/Updates
- Table 33. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
- Table 34. Boehringer Ingelheim Major Business
- Table 35. Boehringer Ingelheim Neurodegenerative Drugs Product and Services
- Table 36. Boehringer Ingelheim Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 37. Boehringer Ingelheim Recent Developments/Updates
- Table 38. Sanofi Basic Information, Manufacturing Base and Competitors
- Table 39. Sanofi Major Business
- Table 40. Sanofi Neurodegenerative Drugs Product and Services
- Table 41. Sanofi Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 42. Sanofi Recent Developments/Updates
- Table 43. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
- Table 44. GlaxoSmithKline Major Business
- Table 45. GlaxoSmithKline Neurodegenerative Drugs Product and Services
- Table 46. GlaxoSmithKline Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 47. GlaxoSmithKline Recent Developments/Updates
- Table 48. Livzon Pharmaceutical Basic Information, Manufacturing Base and Competitors
- Table 49. Livzon Pharmaceutical Major Business
- Table 50. Livzon Pharmaceutical Neurodegenerative Drugs Product and Services
- Table 51. Livzon Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 52. Livzon Pharmaceutical Recent Developments/Updates
- Table 53. Haisco Pharmaceutical Basic Information, Manufacturing Base and Competitors
- Table 54. Haisco Pharmaceutical Major Business
- Table 55. Haisco Pharmaceutical Neurodegenerative Drugs Product and Services
- Table 56. Haisco Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share

(2019-2024)

Table 57. Haisco Pharmaceutical Recent Developments/Updates

Table 58. Jingxin Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 59. Jingxin Pharmaceutical Major Business

Table 60. Jingxin Pharmaceutical Neurodegenerative Drugs Product and Services

Table 61. Jingxin Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 62. Jingxin Pharmaceutical Recent Developments/Updates

Table 63. Dongcheng Biochemicals Basic Information, Manufacturing Base and Competitors

Table 64. Dongcheng Biochemicals Major Business

Table 65. Dongcheng Biochemicals Neurodegenerative Drugs Product and Services

Table 66. Dongcheng Biochemicals Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 67. Dongcheng Biochemicals Recent Developments/Updates

Table 68. Hisun Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 69. Hisun Pharmaceutical Major Business

Table 70. Hisun Pharmaceutical Neurodegenerative Drugs Product and Services

Table 71. Hisun Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 72. Hisun Pharmaceutical Recent Developments/Updates

Table 73. Luye Pharma Basic Information, Manufacturing Base and Competitors

Table 74. Luye Pharma Major Business

Table 75. Luye Pharma Neurodegenerative Drugs Product and Services

Table 76. Luye Pharma Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 77. Luye Pharma Recent Developments/Updates

Table 78. Ark Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 79. Ark Pharmaceutical Major Business

Table 80. Ark Pharmaceutical Neurodegenerative Drugs Product and Services

Table 81. Ark Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 82. Ark Pharmaceutical Recent Developments/Updates

Table 83. Kanghong Pharmaceutical Basic Information, Manufacturing Base and

Competitors

Table 84. Kanghong Pharmaceutical Major Business

Table 85. Kanghong Pharmaceutical Neurodegenerative Drugs Product and Services

Table 86. Kanghong Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 87. Kanghong Pharmaceutical Recent Developments/Updates

Table 88. Huahai Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 89. Huahai Pharmaceutical Major Business

Table 90. Huahai Pharmaceutical Neurodegenerative Drugs Product and Services

Table 91. Huahai Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 92. Huahai Pharmaceutical Recent Developments/Updates

Table 93. BORA PHARMACEUTICALS Basic Information, Manufacturing Base and Competitors

Table 94. BORA PHARMACEUTICALS Major Business

Table 95. BORA PHARMACEUTICALS Neurodegenerative Drugs Product and Services

Table 96. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales Quantity (MT), Average Price (US\$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 97. BORA PHARMACEUTICALS Recent Developments/Updates

Table 98. Global Neurodegenerative Drugs Sales Quantity by Manufacturer (2019-2024) & (MT)

Table 99. Global Neurodegenerative Drugs Revenue by Manufacturer (2019-2024) & (USD Million)

Table 100. Global Neurodegenerative Drugs Average Price by Manufacturer (2019-2024) & (US\$/MT)

Table 101. Market Position of Manufacturers in Neurodegenerative Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023

Table 102. Head Office and Neurodegenerative Drugs Production Site of Key Manufacturer

Table 103. Neurodegenerative Drugs Market: Company Product Type Footprint

Table 104. Neurodegenerative Drugs Market: Company Product Application Footprint

Table 105. Neurodegenerative Drugs New Market Entrants and Barriers to Market Entry

Table 106. Neurodegenerative Drugs Mergers, Acquisition, Agreements, and Collaborations

Table 107. Global Neurodegenerative Drugs Sales Quantity by Region (2019-2024) &

(MT)

Table 108. Global Neurodegenerative Drugs Sales Quantity by Region (2025-2030) & (MT)

Table 109. Global Neurodegenerative Drugs Consumption Value by Region (2019-2024) & (USD Million)

Table 110. Global Neurodegenerative Drugs Consumption Value by Region (2025-2030) & (USD Million)

Table 111. Global Neurodegenerative Drugs Average Price by Region (2019-2024) & (US\$/MT)

Table 112. Global Neurodegenerative Drugs Average Price by Region (2025-2030) & (US\$/MT)

Table 113. Global Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)

Table 114. Global Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)

Table 115. Global Neurodegenerative Drugs Consumption Value by Type (2019-2024) & (USD Million)

Table 116. Global Neurodegenerative Drugs Consumption Value by Type (2025-2030) & (USD Million)

Table 117. Global Neurodegenerative Drugs Average Price by Type (2019-2024) & (US\$/MT)

Table 118. Global Neurodegenerative Drugs Average Price by Type (2025-2030) & (US\$/MT)

Table 119. Global Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)

Table 120. Global Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)

Table 121. Global Neurodegenerative Drugs Consumption Value by Application (2019-2024) & (USD Million)

Table 122. Global Neurodegenerative Drugs Consumption Value by Application (2025-2030) & (USD Million)

Table 123. Global Neurodegenerative Drugs Average Price by Application (2019-2024) & (US\$/MT)

Table 124. Global Neurodegenerative Drugs Average Price by Application (2025-2030) & (US\$/MT)

Table 125. North America Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)

Table 126. North America Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)

Table 127. North America Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)

Table 128. North America Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)

Table 129. North America Neurodegenerative Drugs Sales Quantity by Country (2019-2024) & (MT)

Table 130. North America Neurodegenerative Drugs Sales Quantity by Country (2025-2030) & (MT)

Table 131. North America Neurodegenerative Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 132. North America Neurodegenerative Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 133. Europe Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)

Table 134. Europe Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)

Table 135. Europe Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)

Table 136. Europe Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)

Table 137. Europe Neurodegenerative Drugs Sales Quantity by Country (2019-2024) & (MT)

Table 138. Europe Neurodegenerative Drugs Sales Quantity by Country (2025-2030) & (MT)

Table 139. Europe Neurodegenerative Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 140. Europe Neurodegenerative Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 141. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)

Table 142. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)

Table 143. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)

Table 144. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)

Table 145. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Region (2019-2024) & (MT)

Table 146. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Region

(2025-2030) & (MT)

Table 147. Asia-Pacific Neurodegenerative Drugs Consumption Value by Region (2019-2024) & (USD Million)

Table 148. Asia-Pacific Neurodegenerative Drugs Consumption Value by Region (2025-2030) & (USD Million)

Table 149. South America Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)

Table 150. South America Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)

Table 151. South America Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)

Table 152. South America Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)

Table 153. South America Neurodegenerative Drugs Sales Quantity by Country (2019-2024) & (MT)

Table 154. South America Neurodegenerative Drugs Sales Quantity by Country (2025-2030) & (MT)

Table 155. South America Neurodegenerative Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 156. South America Neurodegenerative Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 157. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)

Table 158. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)

Table 159. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)

Table 160. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)

Table 161. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Region (2019-2024) & (MT)

Table 162. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Region (2025-2030) & (MT)

Table 163. Middle East & Africa Neurodegenerative Drugs Consumption Value by Region (2019-2024) & (USD Million)

Table 164. Middle East & Africa Neurodegenerative Drugs Consumption Value by Region (2025-2030) & (USD Million)

Table 165. Neurodegenerative Drugs Raw Material

Table 166. Key Manufacturers of Neurodegenerative Drugs Raw Materials

Table 167. Neurodegenerative Drugs Typical Distributors

Table 168. Neurodegenerative Drugs Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Neurodegenerative Drugs Picture

Figure 2. Global Neurodegenerative Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Figure 3. Global Neurodegenerative Drugs Consumption Value Market Share by Type in 2023

Figure 4. NMDA Examples

Figure 5. SSRIs Examples

Figure 6. Dopamine Inhibitors Examples

Figure 7. Global Neurodegenerative Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030

Figure 8. Global Neurodegenerative Drugs Consumption Value Market Share by Application in 2023

Figure 9. Parkinson's Disease Examples

Figure 10. Huntington Disease Examples

Figure 11. Amyotrophic Lateral Sclerosis Examples

Figure 12. Alzheimer's Disease Examples

Figure 13. Global Neurodegenerative Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030

Figure 14. Global Neurodegenerative Drugs Consumption Value and Forecast (2019-2030) & (USD Million)

Figure 15. Global Neurodegenerative Drugs Sales Quantity (2019-2030) & (MT)

Figure 16. Global Neurodegenerative Drugs Average Price (2019-2030) & (US\$/MT)

Figure 17. Global Neurodegenerative Drugs Sales Quantity Market Share by Manufacturer in 2023

Figure 18. Global Neurodegenerative Drugs Consumption Value Market Share by Manufacturer in 2023

Figure 19. Producer Shipments of Neurodegenerative Drugs by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2023

Figure 20. Top 3 Neurodegenerative Drugs Manufacturer (Consumption Value) Market Share in 2023

Figure 21. Top 6 Neurodegenerative Drugs Manufacturer (Consumption Value) Market Share in 2023

Figure 22. Global Neurodegenerative Drugs Sales Quantity Market Share by Region (2019-2030)

Figure 23. Global Neurodegenerative Drugs Consumption Value Market Share by

Region (2019-2030)

Figure 24. North America Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)

Figure 25. Europe Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)

Figure 26. Asia-Pacific Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)

Figure 27. South America Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)

Figure 28. Middle East & Africa Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)

Figure 29. Global Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)

Figure 30. Global Neurodegenerative Drugs Consumption Value Market Share by Type (2019-2030)

Figure 31. Global Neurodegenerative Drugs Average Price by Type (2019-2030) & (US\$/MT)

Figure 32. Global Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)

Figure 33. Global Neurodegenerative Drugs Consumption Value Market Share by Application (2019-2030)

Figure 34. Global Neurodegenerative Drugs Average Price by Application (2019-2030) & (US\$/MT)

Figure 35. North America Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)

Figure 36. North America Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)

Figure 37. North America Neurodegenerative Drugs Sales Quantity Market Share by Country (2019-2030)

Figure 38. North America Neurodegenerative Drugs Consumption Value Market Share by Country (2019-2030)

Figure 39. United States Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 40. Canada Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 41. Mexico Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 42. Europe Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)

Figure 43. Europe Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)

Figure 44. Europe Neurodegenerative Drugs Sales Quantity Market Share by Country (2019-2030)

Figure 45. Europe Neurodegenerative Drugs Consumption Value Market Share by Country (2019-2030)

Figure 46. Germany Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 47. France Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 48. United Kingdom Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 49. Russia Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 50. Italy Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 51. Asia-Pacific Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)

Figure 52. Asia-Pacific Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)

Figure 53. Asia-Pacific Neurodegenerative Drugs Sales Quantity Market Share by Region (2019-2030)

Figure 54. Asia-Pacific Neurodegenerative Drugs Consumption Value Market Share by Region (2019-2030)

Figure 55. China Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 56. Japan Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 57. Korea Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 58. India Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 59. Southeast Asia Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 60. Australia Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 61. South America Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)

Figure 62. South America Neurodegenerative Drugs Sales Quantity Market Share by

Application (2019-2030)

Figure 63. South America Neurodegenerative Drugs Sales Quantity Market Share by Country (2019-2030)

Figure 64. South America Neurodegenerative Drugs Consumption Value Market Share by Country (2019-2030)

Figure 65. Brazil Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 66. Argentina Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 67. Middle East & Africa Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)

Figure 68. Middle East & Africa Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)

Figure 69. Middle East & Africa Neurodegenerative Drugs Sales Quantity Market Share by Region (2019-2030)

Figure 70. Middle East & Africa Neurodegenerative Drugs Consumption Value Market Share by Region (2019-2030)

Figure 71. Turkey Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 72. Egypt Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 73. Saudi Arabia Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 74. South Africa Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 75. Neurodegenerative Drugs Market Drivers

Figure 76. Neurodegenerative Drugs Market Restraints

Figure 77. Neurodegenerative Drugs Market Trends

Figure 78. Porters Five Forces Analysis

Figure 79. Manufacturing Cost Structure Analysis of Neurodegenerative Drugs in 2023

Figure 80. Manufacturing Process Analysis of Neurodegenerative Drugs

Figure 81. Neurodegenerative Drugs Industrial Chain

Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors

Figure 83. Direct Channel Pros & Cons

Figure 84. Indirect Channel Pros & Cons

Figure 85. Methodology

Figure 86. Research Process and Data Source

I would like to order

Product name: Global Neurodegenerative Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Product link: <https://marketpublishers.com/r/G7681DB79DE8EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7681DB79DE8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

